Product Informationfor the Patient
Everolimus Viatris 10mg Tablets EFG
Read this entire product information carefully before starting to take this medicine, as it contains important information for you.
1.What is Everolimus Viatris and for what it is used
2.What you need to know before starting to take Everolimus Viatris
3.How to take Everolimus Viatris
4.Possible adverse effects
5.Storage of Everolimus Viatris
6.Contents of the package and additional information
Everolimus is a cancer medication that contains the active ingredient everolimus. Everolimus reduces blood supply to the tumor and delays the growth and spread of cancer cells.
Everolimus is used to treat adult patients with:
Everolimus will only be prescribed to you by an experienced doctor in cancer treatment. Follow all the doctor's instructions carefully. They may be different from the general information contained in this prospectus. If you have any doubts about everolimus or the reason why you have been prescribed this medication, consult your doctor.
Do not take Everolimus Viatris:
If you think you may be allergic, consult your doctor.
Warnings and precautions
Consult your doctor before starting to take Everolimus Viatris:
Everolimus may also:
-Weaken your immune system. Therefore, you may be at risk of infection
while taking everolimus. If you have a fever or other signs of infection, consult your doctor. Some infections can be serious and fatal.
-Affect kidney function. Therefore, your doctor will monitor your kidney function while taking everolimus.
-Causing difficulty breathing, coughing, and fever.
-Cause mouth ulcers and sores. Your doctor may need to interrupt or discontinue Everolimus Viatris treatment. You may need treatment with a mouthwash, gel, or other products. Some mouthwashes and gels may worsen ulcers, so do not try any without consulting your doctor first. Your doctor may restart Everolimus Viatris treatment at the same dose or a lower dose.
-Cause radiation therapy complications. Severe radiation therapy complications (such as difficulty breathing, nausea, diarrhea, skin rash, and mouth, gum, and throat pain), including fatal cases, have been observed in some patients taking everolimus at the same time as receiving radiation therapy or taking everolimus shortly after receiving radiation therapy. Radiation recall syndrome (presenting with skin redness or lung inflammation at the site of previous radiation therapy) has also been reported in patients who had received radiation therapy in the past.
Inform your doctor if you are scheduled to receive radiation therapy soon, or if you have received radiation therapy previously.
Inform your doctorif you experience these symptoms.
During treatment, you will have blood tests performed periodically. These tests will determine the number of blood cells (white blood cells, red blood cells, and platelets) to check if everolimus is having an undesirable effect on these cells. You will also have blood tests to monitor kidney function (creatinine level), liver function (transaminase level), and blood sugar and cholesterol levels. These tests are done because these may be affected by everolimus treatment.
Children and adolescents
Everolimus should not be administered to children or adolescents (under 18 years old).
Other medications and Everolimus Viatris
Everolimus may affect how other medications work. If you are taking other medications at the same time as everolimus, your doctor may change the dose of everolimus or the other medications.
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
The following may increase the risk of adverse effects with everolimus:
used to treat fungal infections.
The following may reduce the effectiveness of everolimus:
You should avoid using these medications during everolimus treatment. If you are taking any of them, your doctor may prescribe a different medication or change your everolimus dose.
Taking Everolimus Viatris with food and drinks
Do not take grapefruit or grapefruit juice while taking everolimus. It may increase the amount of everolimus in your blood, possibly to a harmful level.
Pregnancy, breastfeeding, and fertility
Pregnancy
Everolimus may cause harm to the fetus and is not recommended for use during pregnancy. Inform your doctor if you are pregnant or think you may be pregnant. Your doctor will discuss with you whether you should take this medication during pregnancy.
Women who may become pregnant should use a highly effective contraceptive method during treatment and for 8 weeks after stopping treatment. If, despite these measures, you think you may be pregnant, consult your doctorbeforetaking more everolimus.
Breastfeeding
Everolimus may harm the breastfeeding baby. Do not breastfeed during treatment and for 2 weeks after the last dose of everolimus. Inform your doctor if you are breastfeeding.
Female fertility
Some patients treated with everolimus have experienced amenorrhea (absence of menstrual periods).
Everolimus may affect female fertility. Inform your doctor if you want to have children.
Male fertility
Everolimus may affect male fertility. Consult your doctor if you want to be a father.
Driving and operating machinery
If you feel abnormally tired (fatigue is a very common side effect), be especially careful when driving or operating machinery.
Everolimus Viatris contains lactose
Everolimus Viatris contains lactose (milk sugar). If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
The recommended dose is 10 mg, once a day. Your doctor will inform you about how many everolimus tablets you should take.
If you have liver problems, your doctor may start treatment with a lower dose of everolimus (2.5; 5 or 7.5 mg per day).
If you experience some adverse effects while taking everolimus (see section 4), your doctor may reduce the dose you take or interrupt treatment for a short period of time or permanently.
Take everolimus once a day, more or less at the same time, always with food or always without food.
Swallow the tablets whole with a glass of water. The tablets should not be chewed or crushed.
If you take more Everolimus Viatris than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service (Tel. 91 562 04 20) indicating the medication and the amount ingested.
If you forget to take Everolimus Viatris
If you have forgotten a dose, take the next dose at the time it is due. Do not take a double dose to make up for the missed doses.
If you interrupt treatment with Everolimus Viatris
Do not stop treatment with everolimus unless your doctor tells you to.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
STOP treatment with everolimus and seek medical help immediately if you experience any of the following signs of an allergic reaction:
-Intense itching of the skin, with red rash or lumps on the skin.
The serious side effects of everolimus include:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Potential signs of pulmonary embolism, a situation that occurs when one or more arteries in the lungs are blocked)
Rare(may affect up to 1 in 1,000 people)
If you experience any of these side effects, report them to your doctor immediately, as they may have fatal consequences.
Other possible side effects of everolimus include:
Very common(may affect more than 1 in 10 people)
glóbulos rojos (anemia).
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Unknown frequency(cannot be estimated from available data)
If these adverse reactions worsen, report them to your doctor and/or pharmacist. Most side effects are mild to moderate and usually disappear if treatment is interrupted for a few days.
Reporting of adverse reactions
If you experience any type of adverse reaction, consult your doctor or pharmacist, even if it is a possible adverse reaction that does not appear in this prospectus. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use: https://www.notificaram.es. By reporting adverse reactions, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and on the
blister after CAD. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from light.
This medication does not require special temperature conditions for storage.
Medicines should not be thrown down the drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. In this way, you will help protect the environment.
Everolimus Viatris Composition
Appearance of Everolimus Viatris and packaging contents
Everolimus Viatris are biconvex, oval-shaped, white or off-white tablets with "E9VS 10" engraved on one side.
Everolimus Viatris is supplied in blister packs containing 30 or 90tablets, or blister packs containing 30tablets in single-dose perforated blisters.
Only some packaging sizes may be marketed.
Marketing Authorization Holder
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Manufacturer
Synthon Hispania S.L.
Castelló 1
Polígono Las Salinas
08830 Sant Boi de Llobregat
Spain
Or
Synthon BV
Microweg 22
6545 CM Nijmegen
Netherlands
For more information about this medication, please contact the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.
C/ General Aranaz, 86
28027 - Madrid
Spain
This medication is authorized in the member states of the European Economic Areaand in the United Kingdom (Northern Ireland)with the following names:
GermanyEverolimus Mylan 10 mg Tabletten
BulgariaEverolimus Viatris 10 mg tablets
CroatiaEverolimus Viatris 10 mg tablete
DenmarkEverolimus Viatris, 10 mg tabletter
SpainEverolimus Viatris 10 mg comprimidos EFG
FinlandEverolimus Viatris, 10 mg tabletti
FranceEverolimus Mylan 10 mg comprimés
ItalyEverolimus Mylan 10 mg compresse
NorwayEverolimus Viatris, 10 mg tabletter
NetherlandsEverolimus Viatris 10 mg, tabletten
PortugalEverolimus Mylan
United Kingdom (Northern Ireland)Everolimus Mylan 10 mg tablets
SwedenEverolimus Viatris, 10 mg tabletter
Last review date of this leaflet: December 2022
For detailed and updated information about this medication, please visit the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)https://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.